Equities

PetVivo Holdings Inc

PETV:PKC

PetVivo Holdings Inc

Actions
  • Price (USD)0.65
  • Today's Change-0.001 / -0.11%
  • Shares traded20.48k
  • 1 Year change-67.34%
  • Beta2.2297
Data delayed at least 15 minutes, as of May 23 2024 14:46 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

PetVivo Holdings, Inc. is a biomedical device company. The Company is focused on the manufacturing, commercialization, and licensing of medical devices and therapeutics for animals. The Company’s lead product Spryng with OsteoCushion Technology, is a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The Company is primarily engaged in the business of commercializing and licensing products in the veterinary market to treat and/or manage afflictions of companion animals, such as dogs and horses. Its products are derived from biomaterials that simulate a body’s cellular tissue by virtue of their reliance upon natural protein and carbohydrate compositions, which incorporate such tissue building blocks as collagen, elastin, and proteoglycans such as heparin. The Company has a pipeline of therapeutic devices for both veterinary and human clinical applications.

  • Revenue in USD (TTM)1.05m
  • Net income in USD-10.63m
  • Incorporated2009
  • Employees25.00
  • Location
    PetVivo Holdings Inc5251 Edina Industrial BlvdEDINA 55439United StatesUSA
  • Phone+1 (952) 217-4952
  • Fax+1 (775) 884-9383
  • Websitehttps://petvivo.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sonendo Inc40.19m-57.74m6.36m216.00--0.259--0.1581-0.6125-0.55520.4260.34820.44482.077.58186,055.60-63.91---78.82--27.64---143.67--2.14-10.830.4695--5.30---6.78------
BIOLASE Inc49.16m-37.62m6.41m157.00------0.1304-37.97-37.9738.540.57261.342.388.68313,146.50-56.30-49.28-115.21-85.8034.0235.27-41.97-50.720.683-6.610.8778--1.451.27-30.39--18.63--
Sigyn Therapeutics Inc0.00-3.56m6.43m5.00---------3.04-3.040.00-3.280.00----0.00-724.37-493.15-----------10,223.960.0199-1.92---------41.51------
Arch Therapeutics Inc130.55k-8.43m6.58m8.00------50.38-3.68-3.680.0425-2.450.08330.0637--16,318.75-538.25-188.28---804.6333.37---6,458.14-26,945.920.0164-1.27----383.83---32.35---21.76--
Predictive Oncology Inc1.96m-14.78m6.69m34.00--1.63--3.41-3.66-3.660.48530.99770.10991.714.9557,642.65-82.89-91.80-108.54-126.2964.1864.64-754.19-1,419.991.35--0.0093--18.244.7545.67--5.44--
Vivos Therapeutics Inc13.36m-15.64m6.87m114.00--10.00--0.5144-11.00-11.008.730.21310.9247--31.59117,219.30-108.24-89.72-243.30-149.7058.9070.20-117.06-113.15----0.00---13.8729.4843.04---8.48--
Neurometrix Inc5.27m-7.98m7.72m26.00--0.4068--1.47-6.32-6.324.209.440.23811.2510.08202,700.40-36.07-23.24-38.94-27.2661.9759.17-151.51-48.8810.11--0.00---28.52-18.18-47.84--5.03--
Nexalin Technology Inc158.86k-4.94m8.55m6.00--3.68--53.83-0.6676-0.66760.02150.31290.03630.177844.0126,476.67-112.76---139.94--82.54---3,110.58--4.75--0.00---91.62---173.80------
Citrine Global Corp0.00-2.38m9.66m18.00---------0.0025-0.00250.00-0.00280.00----0.00-173.12-298.98---964.26-------4,814.84---5.41--------41.43---5.44--
Biomerica Inc5.41m-6.35m10.65m62.00--1.36--1.97-0.3789-0.37890.32240.46420.58272.285.7487,180.80-68.45-43.55-83.73-50.3211.4115.75-117.46-55.863.37--0.00---71.71-0.8229-57.58---9.76--
PetVivo Holdings Inc1.05m-10.63m11.10m25.00--10.85--10.61-0.8694-0.86940.08420.060.33751.212.0441,841.60-343.12-209.90-715.73-504.6451.4120.27-1,016.55-2,297.210.6169-2,268.840.1392--693.46260.32-73.83--51.73--
SINTX Technologies Inc2.78m-8.88m11.36m43.00--0.4765--4.09-1.95-1.950.37110.19430.1381.625.8464,534.88-44.03-45.71-57.11-57.3667.9658.47-318.99-681.801.67--0.0229--68.2994.2449.75--54.10--
ALR Technologies Inc9.49k-8.00m12.07m6.00------1,272.27-0.0147-0.01470.00002-0.04760.0358----1,581.67-3,015.28-12,861.64----62.49---84,283.24-406,011.30---0.8626---------42.72------
STRATA Skin Sciences Inc32.55m-11.36m13.36m99.00--1.42--0.4105-0.3248-0.32480.93070.2690.733.678.60328,737.40-25.49-11.48-35.77-16.5552.7161.28-34.91-17.700.8376-3.900.6151---7.752.24-95.17--23.29--
Biotricity Inc11.63m-15.39m14.13m55.00------1.22-1.75-1.751.32-2.841.922.016.55211,408.70-240.40-303.46----65.5253.00-125.43-368.780.1012-0.5855----26.00--35.36------
Data as of May 23 2024. Currency figures normalised to PetVivo Holdings Inc's reporting currency: US Dollar USD

Institutional shareholders

3.24%Per cent of shares held by top holders
HolderShares% Held
Bard Associates, Inc.as of 31 Mar 2024418.80k2.50%
Geode Capital Management LLCas of 31 Mar 202461.08k0.36%
Regal Investment Advisors LLCas of 31 Mar 202419.00k0.11%
Asset Dedication LLCas of 31 Mar 202414.57k0.09%
Boothbay Fund Management LLCas of 31 Mar 202413.89k0.08%
Cetera Advisor Networks LLCas of 31 Mar 202410.00k0.06%
Tower Research Capital LLCas of 31 Mar 20245.32k0.03%
Bank of America, NA (Private Banking)as of 31 Mar 20241.00k0.01%
Delos Wealth Advisors LLCas of 31 Mar 20245.000.00%
The Vanguard Group, Inc.as of 30 Apr 20240.000.00%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.